Cargando…

Assessing immunogenicity barriers of the HIV-1 envelope trimer

Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Maliqi, Liridona, Friedrich, Nikolas, Glögl, Matthias, Schmutz, Stefan, Schmidt, Daniel, Rusert, Peter, Schanz, Merle, Zaheri, Maryam, Pasin, Chloé, Niklaus, Cyrille, Foulkes, Caio, Reinberg, Thomas, Dreier, Birgit, Abela, Irene, Peterhoff, David, Hauser, Alexandra, Kouyos, Roger D., Günthard, Huldrych F., van Gils, Marit J., Sanders, Rogier W., Wagner, Ralf, Plückthun, Andreas, Trkola, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542815/
https://www.ncbi.nlm.nih.gov/pubmed/37777519
http://dx.doi.org/10.1038/s41541-023-00746-3
_version_ 1785114174134681600
author Maliqi, Liridona
Friedrich, Nikolas
Glögl, Matthias
Schmutz, Stefan
Schmidt, Daniel
Rusert, Peter
Schanz, Merle
Zaheri, Maryam
Pasin, Chloé
Niklaus, Cyrille
Foulkes, Caio
Reinberg, Thomas
Dreier, Birgit
Abela, Irene
Peterhoff, David
Hauser, Alexandra
Kouyos, Roger D.
Günthard, Huldrych F.
van Gils, Marit J.
Sanders, Rogier W.
Wagner, Ralf
Plückthun, Andreas
Trkola, Alexandra
author_facet Maliqi, Liridona
Friedrich, Nikolas
Glögl, Matthias
Schmutz, Stefan
Schmidt, Daniel
Rusert, Peter
Schanz, Merle
Zaheri, Maryam
Pasin, Chloé
Niklaus, Cyrille
Foulkes, Caio
Reinberg, Thomas
Dreier, Birgit
Abela, Irene
Peterhoff, David
Hauser, Alexandra
Kouyos, Roger D.
Günthard, Huldrych F.
van Gils, Marit J.
Sanders, Rogier W.
Wagner, Ralf
Plückthun, Andreas
Trkola, Alexandra
author_sort Maliqi, Liridona
collection PubMed
description Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, high diversity, Designed Ankyrin Repeat Protein (DARPin) libraries. We show that DARPin Antigenicity Analysis (DANA), a purely in vitro screening tool, has the capability to extrapolate relevant information of antigenic properties of Env immunogens. DANA screens of stabilized, soluble Env trimers revealed that stronger trimer stabilization led to the selection of highly mutated DARPins with length variations and framework mutations mirroring observations made for bnAbs. By mimicking heterotypic prime-boost immunization regimens, DANA may be used to select immunogen combinations that favor the selection of trimer-reactive binders. This positions DANA as a versatile strategy for distilling fundamental antigenic features of immunogens, complementary to preclinical immunogenicity testing.
format Online
Article
Text
id pubmed-10542815
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105428152023-10-03 Assessing immunogenicity barriers of the HIV-1 envelope trimer Maliqi, Liridona Friedrich, Nikolas Glögl, Matthias Schmutz, Stefan Schmidt, Daniel Rusert, Peter Schanz, Merle Zaheri, Maryam Pasin, Chloé Niklaus, Cyrille Foulkes, Caio Reinberg, Thomas Dreier, Birgit Abela, Irene Peterhoff, David Hauser, Alexandra Kouyos, Roger D. Günthard, Huldrych F. van Gils, Marit J. Sanders, Rogier W. Wagner, Ralf Plückthun, Andreas Trkola, Alexandra NPJ Vaccines Article Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, high diversity, Designed Ankyrin Repeat Protein (DARPin) libraries. We show that DARPin Antigenicity Analysis (DANA), a purely in vitro screening tool, has the capability to extrapolate relevant information of antigenic properties of Env immunogens. DANA screens of stabilized, soluble Env trimers revealed that stronger trimer stabilization led to the selection of highly mutated DARPins with length variations and framework mutations mirroring observations made for bnAbs. By mimicking heterotypic prime-boost immunization regimens, DANA may be used to select immunogen combinations that favor the selection of trimer-reactive binders. This positions DANA as a versatile strategy for distilling fundamental antigenic features of immunogens, complementary to preclinical immunogenicity testing. Nature Publishing Group UK 2023-09-30 /pmc/articles/PMC10542815/ /pubmed/37777519 http://dx.doi.org/10.1038/s41541-023-00746-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Maliqi, Liridona
Friedrich, Nikolas
Glögl, Matthias
Schmutz, Stefan
Schmidt, Daniel
Rusert, Peter
Schanz, Merle
Zaheri, Maryam
Pasin, Chloé
Niklaus, Cyrille
Foulkes, Caio
Reinberg, Thomas
Dreier, Birgit
Abela, Irene
Peterhoff, David
Hauser, Alexandra
Kouyos, Roger D.
Günthard, Huldrych F.
van Gils, Marit J.
Sanders, Rogier W.
Wagner, Ralf
Plückthun, Andreas
Trkola, Alexandra
Assessing immunogenicity barriers of the HIV-1 envelope trimer
title Assessing immunogenicity barriers of the HIV-1 envelope trimer
title_full Assessing immunogenicity barriers of the HIV-1 envelope trimer
title_fullStr Assessing immunogenicity barriers of the HIV-1 envelope trimer
title_full_unstemmed Assessing immunogenicity barriers of the HIV-1 envelope trimer
title_short Assessing immunogenicity barriers of the HIV-1 envelope trimer
title_sort assessing immunogenicity barriers of the hiv-1 envelope trimer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542815/
https://www.ncbi.nlm.nih.gov/pubmed/37777519
http://dx.doi.org/10.1038/s41541-023-00746-3
work_keys_str_mv AT maliqiliridona assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT friedrichnikolas assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT gloglmatthias assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT schmutzstefan assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT schmidtdaniel assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT rusertpeter assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT schanzmerle assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT zaherimaryam assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT pasinchloe assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT niklauscyrille assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT foulkescaio assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT reinbergthomas assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT dreierbirgit assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT abelairene assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT peterhoffdavid assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT hauseralexandra assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT kouyosrogerd assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT gunthardhuldrychf assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT vangilsmaritj assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT sandersrogierw assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT wagnerralf assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT pluckthunandreas assessingimmunogenicitybarriersofthehiv1envelopetrimer
AT trkolaalexandra assessingimmunogenicitybarriersofthehiv1envelopetrimer